MED13 and leiomyoma: This aligns with recently published data in heterologous cell lines as well as leiomyoma tissue samples, which demonstrate that the presence of MED13 is a stabilizing protein in the submodule that compensates for any MED12 mutant-dependent interaction defect51,52.